Data Supports Temelimab's Potential to Treat Disease Progression in MS Long-term neuroprotective effects confirmed in patients treated up to two years Sustained benebits on cortical and thalamic atrophy and my ...
Top line results expected in spring 2019 GKT 831 exhibited a favorable safety profile throughout the study No drop outs or treatment interruptions due to pruritus 2 SAEs recorded in the study, both unrelat ...
10-for-1 reverse stock split: 10 existing shares with par value of €0.10 for 1 new share with par value of €1.00 Start date of the reverse stock split operation: February 27, 2019 Reverse stock split will bec ...
Professor Gareth Thomas of Southampton University Awarded Second Grant from Cancer Research UK for Further Evaluation of GKT831 in Oncology Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharma ...
International Nonproprietary Name "temelimab" Assigned to GNbAC1 Temelimab’s robust safety and tolerability profile confirmed High-dose regimen fully validated by pharmacokinetic data Enables higher dos ...
NETRIS Pharma successfully completes first clinical study with first-in-class netrin-1 inhibitor NP137 in patients with advanced solid tumors Dose-escalation part of study met primary objective Study shows NP137 to hav ...
